DEI01 - Gender Equity in Thoracic Oncology

DEI02 - Beyond Equity: Creating Understanding in Thoracic Oncology

ES01 - Mesothelioma

ES02 - Improving Access to Lung Cancer Screening and Early Detection

ES03 - Joint IASLC & GLCC Session

ES04 - Challenges and Controversies in Immunotherapy

ES05 - Cancer Evolution and Cancer Heterogeneity

ES06 - Novel Local and Biomarker Driven Therapeutic Options for SCLC

ES07 - Risk Factors in Early Stage Lung Cancer

ES08 - Lung Cancer Staging: Updates, Limitations, Approach and Guidelines

ES09 - Patient Advocates Role: Overcoming Access Barriers

ES10 - First-Line Treatment of EGFR-Mutant NSCLC: TKI Alone or Combinations - What I Use Today and Why

ES11 - "Shining the Light" on Lung Neuroendocrine Neoplasms

ES12 - Why Attending to Tobacco Matters in Lung Cancer

ES13 - The Grey Zone for Systemic Therapies in Locally Advanced NSCLC, Defining Practice With Minimal Evidence

ES14 - Combined Pathology-Surgery Session

ES15 - Global Aspects of Patients Care

ES16 - Chemotherapy in Patients With Driver Mutations

ES17 - Metastatic NSCLC as a Chronic Disease - How Is Quality of Life Impacted?

ES18 - Debate: Latest and Greatest Multimodality Treatment Options in Early Stage NSCLC

ES19 - Mesothelioma, Thymoma, and Other Thoracic Tumors

ES20 - Expanding Eligibility for Lung Cancer Screening

ES21 - Patient Navigation and Social Justice: Case Presentation

ES22 - Novel Immunotherapeutics: Raising the Bar

ES23 - Preclinical Evaluation of Exposure to Air Contaminants

ES24 - Novel Immunotherapy Options for Patients With Neuroendocrine Tumors

ES25 - Latest and Greatest: Practice Updates in the Management of Early Stage Lung Cancers

ES26 - Augmented Techniques for Lung Cancer Diagnosis Prognosis and Predicting Response

ES27 - Patient Advocates Perspectives: Impact of Care and Connection on Patient Outcomes

ES28 - Management of Brain Metastases in Oncogene Driven NSCLC

ES29 - Immunotherapy: Moving Beyond PD-1/PD-L1 and CTLA4

ES30 - Lung Cancer Beyond Smoking

ES31 - Surgical Challenges and Opportunities in Locally Advanced NSCLC

ES32 - Biomarkers for Lung Cancer in 2024

ES33 - Global Aspects of Access to Precision Oncology

ES34 - Antibody Drug Conjugates: Current Evidence

ES35 - Disparities and Timing in the Delivery of Local Therapy for Oligometastatic NSCLC

ES36 - Joint IASLC – ESTRO Session

ES37 - Implementing Lung Cancer Screening Around the World

ES38 - Advanced Cancer Survivorship

ES39 - Biomarkers and Beyond

ES40 - Trial Design in the Early Stage Space: Concerns and Controversies

ES41 - Pulmonary & Pleural Complications in Pulmonary Malignancy

ES42 - The Rest of the Pie: State of the Art for "Other" Targets

ES43 - Latest Advances in Unresectable Local-Regional NSCLC

ES44 - Updates on Lung Cancer Pathology 2024

ES45 - Intensifying Suboptimal Response to Targeted Therapy

HOD01 - Highlights of the Day - Sunday Abstracts

HOD02 - Highlights of the Day - Monday Abstracts

HW01 - Navigating the Emotional Aftermath of Challenging Patient Outcomes

IASLC01 - IASLC Business Meeting

MA01 - Advances in Treatment for Stage III NSCLC

MA02 - Innovation in Lung Cancer Screening and Early Lung Cancer Detection

MA03 - The Science of Sublobar Resection

MA04 - Real-world Implementation of Early Lung Cancer Detection

MA05 - Treatment Targets and Monitoring Markers for Mesothelioma and Thymic Tumors

MA06 - New Strategies in ALK, ROS1, NTRK, BRAF, and MET NSCLC

MA07 - Novel Targets to Overcome Resistance to Therapy

MA08 - Pulmonary Nodes and Nodules

MA09 - Beyond the Microscope: Predicting Benefit and Understanding Biology through Biomarkers

MA10 - Financial Toxicity, Clinical Communication, and the Needs of Patients and Caregivers

MA11 - Building on the Foundations of Current Immunotherapies

MA12 - Paving the Path to Precision Oncology: Targeting EGFR and HER2

MA13 - Advancing Lung Cancer Prevention through Understanding Risk Factors

MA14 - Global Perspectives of Lung Cancer Across the Care Continuum

MA15 - Paradigm Shifts in Recurrence Assessment After Surgery

MA16 - Strategies Beyond Current Immunotherapies

MA17 - Limited-stage SCLC, Novel Immunotherapy Combinations and Biomarkers in SCLC

MA18 - New Paradigms in Lung Cancer Screening

MA19 - Innovative Therapeutic Approaches and Molecular Insights in Lung Cancer

MTE01 - Is There a Role for Surgery in Pleural Mesothelioma?

MTE02 - Balancing the Risks and Benefits of Lung Cancer Screening When Selecting Individuals for Screening: Case-based Scenarios

MTE03 - Digital Health for Supportive Care Delivery

MTE04 - A Marathon or a Sprint? Defining the Duration of Immunotherapy

MTE05 - Advances in Cell Therapy in Lung Cancer (Adoptive T Cell Transfer, CAR T Cells). The Perspective of a Patient Advocate

MTE06 - Role for Thoracic RT in ES-SCLC in the Era of Immunotherapy

MTE 07 - Putting Evidence Into Practice

MTE08 - Radiological Challenges in Lung Caner

MTE09 - Patient Research Advocates Contributions to Research

MTE10 - Quiz Show: Do You Know Your Targets?

MTE11 - Drugging the Undruggable - Lessons Learnt from Targeting KRAS Driven Lung Cancers

MTE12 - Occupational Exposure & Lung Cancer

MTE13 - Biomarkers of Response

MTE14 - NGS Testing for Targeted Therapy in Lung Cancer - Combined Pathology-Oncology Session

MTE15 - Access to Surgery and Radiotherapy

MTE16 - How Well Do You Know Your Antibody Drug Conjugates

MTE17 - Management of the Primary Tumor in Oligometastatic NSCLC with Isolated Brain Metastases

OA01 - Perioperative Strategies 1

OA02 - Redefining First-Line EGFR Therapy

OA03 - Predicting the Future: Novel Pathology Assessments and Imaging Biomarkers

OA04 - Antibody Drug Conjugates in SCLC

OA05 - Local Consolidative Therapy for Metastatic NSCLC

OA06 - Novel Immunotherapy Strategies and Combinations

OA07 - Opportunities for Optimizing Supportive Care

OA08 - The New Generation of Cytotoxics

OA09 - Trailblazing Targets: New Insights

OA10 - DLL3 Targeting BiTE Therapies in SCLC

OA11 - Shifting the Bar in the Front Line Immunotherapy Setting

OA12 - Advancing Multimodal Therapies in Stage III NSCLC

OA13 - Perioperative Strategies 2

OA14 - New Horizons in Targeting KRAS G12C

OA15 - Profiling the Tumour Microenvironment of Lung Cancer Metastasis

OA16 - Transforming Cancer Therapy: Biomarkers and Novel ADCs

OA17 - Increasing Access to Early Lung Cancer Detection

OA18 - Pleural, Mediastinal and Undifferentiated Thoracic Cancers

PL01 - Opening Plenary with Distinguished Service Award Presentations

PL02 - Presidential Symposium I

PL03 - Celebrating 50 Years of the IASLC, Legacy of Impact, Future of Promise

PL04 - Presidential Symposium II

PL05 - Unmasking Lung Cancer - Exploring the Rising Influence of Non-Tobacco Factors

PL06 - IASLC Lectureship Award Presentations

PL07 - Closing Plenary - Breaking Barriers, Building Bridges - Advancing Patient Advocacy Worldwide

WS01 - Pathfinding Clinically Useful Early Diagnostics from Bench to Bedside: A Hands on Workshop

WS02 - Joint IASLC-CSCO-CAALC Session - Prevention and Evidenced-based Medicine: The Past and Future for Lung Cancer Globally

WS03 - Persuasive Communication

WS04 - Radiation Oncology Workshop

WS05 - Early Career Investigator Workshop

WS07 - The Multidisciplinary Team and Challenging Real-World Treatment Decisions for Patients with Locally Advanced NSCLC

WS08 - Model-Assisted Designs: Make Bayesian Adaptive Clinical Trials Easy and Accessible

WS09 - IASLC/iMig Workshop

WS10 - ITONF AGM for ITONF Members

WS11 - Successful IASLC Grant Application

WS12 - Understanding and Managing Compassion Fatigue

WS13 - Joint IASLC – ASCO Session: Art & Science of Cancer Care: Optimizing Whole-Person Care for Early-Stage Lung Cancer

WS14 - Social Media & Communications Workshop

WS16 - AABIP-IASLC Session on Peripheral Lung Cancer Therapeutics

WS17 - LATAM Workshop: Challenges and Future of Lung Cancer in Latin America